PharmaEssentia Corporation
6446
Rangering i aksjer
#1448
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aksjekurs
$35.96
Markedsverdi
$14.87B
Endring (1 dag)
-0.85%
Endring (1 år)
138.77%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Aksjeprishistorikk for PharmaEssentia Corporation (6446)
Høyeste sluttskurs: $37.51 den 2026-10-01
Laveste sluttskurs: $4.95 den 2014-03-01
Laveste sluttskurs: $4.95 den 2014-03-01
Aksjeprishistorikk for PharmaEssentia Corporation fra 2014 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.71 | 20.94% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $223.29 | 30.39% |
CH
|
|
| $18.49 | -3.70% |
IN
|
